Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.60 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4741474 | 0.83 | GPBAR1 (0.69) | PDGFRBPDGFRAGPBAR1NPC1MAOB | |
| SCHEMBL4740926 | 0.81 | GPBAR1 (0.59) | PDGFRBPDGFRAGPBAR1NPC1MAOB | |
| SCHEMBL17942774 | 0.80 | KDM4E (0.55) | GPBAR1NPC1NCF1RAD51 | |
| SCHEMBL4740452 | 0.80 | GPBAR1 (0.56) | PDGFRBPDGFRAGPBAR1NPC1MAOB | |
| SCHEMBL4743289 | 0.79 | GPBAR1 (0.66) | PDGFRBPDGFRAGPBAR1NPC1MAOB | |
| SCHEMBL4741387 | 0.79 | GPBAR1 (0.57) | PDGFRBPDGFRAGPBAR1NPC1MAOB | |
| SCHEMBL4880446 | 0.75 | GPBAR1 (1.00) | PDGFRBPDGFRAGPBAR1 | |
| SCHEMBL8500071 | 0.75 | PDGFRB (1.00) | PDGFRBPDGFRAGPBAR1NPC1 | |
| SCHEMBL31060313 | 0.75 | PDGFRB (1.00) | PDGFRBPDGFRAGPBAR1NPC1 | |
| SCHEMBL4871712 | 0.74 | GPBAR1 (0.76) | PDGFRBPDGFRAGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008097976-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | GPR119, GPBAR1, LDLR | PDGFRB 1505/4885PDGFRA 1411/4885GPBAR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.